Forecast
| Buy |
Â
6 |
| Hold |
Â
5 |
| Sell |
Â
2 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Spero Therapeutics receives $105 million from KKR unit, stock falls
Spero Therapeutics entered into a $105 million licensing and financing agreement with subsidiaries of Healthcare Royalty (KKR). HCRx will receive a portion of milestone and royalty payments from GSK’s Utebzi sales and will receive quarterly principal and interest payments from those receipts; after full repayment Spero will retain 35% of subsequent GSK payments. The funds will be used primarily to advance the phase-2 immunology candidate SP001, and Spero’s cash runway has been extended into the second half of 2029. The announcement pushed Spero’s stock down about 12% in premarket trading. » More on de.investing.com
Spero Therapeutics secures $105 million financing from KKR unit for SP001 development
Spero Therapeutics agreed a non‑recourse royalty financing of $105 million with Healthcare Royalty (KKR), assigning part of future milestone and license payments from Utebzi sales. The funds will finance development of SP001, a monoclonal anti‑CD40L antibody intended for Phase 2; simultaneously Spero signed an exclusive licensing agreement with Innovent for SP001. Healthcare Royalty will receive quarterly principal and interest payments from GSK payments, and after repayment Spero will retain 35% of subsequent GSK payments; Spero thereby extends its cash runway into the second half of 2029 and reports a current ratio of 10.5. » More on de.investing.com
Spero Therapeutics rises 16% after FDA approval for Utebzi
Shares of Spero Therapeutics climbed 16% after the FDA approved Utebzi, an oral carbapenem developed with GSK to treat complicated urinary tract infections in adults with limited oral options. Utebzi is the first oral carbapenem approved in the U.S.; the approval is based on the Phase III PIVOT-PO study, which showed noninferiority to intravenous imipenem‑cilastatin. The drug is expected to be available in the U.S. by the end of 2026; development was partially supported by BARDA. » More on de.investing.com
Spero Therapeutics: board member Mahadevia resigns, SEC ends investigation
Dr. Ankit Mahadevia has resigned from the board of Spero Therapeutics with immediate effect and has also relinquished his committee and subsidiary mandates; the company cites other professional commitments for the resignation. Spero plans to engage Mahadevia as a consultant to continue supporting management. The U.S. securities regulator SEC said that, based on available information, it currently does not intend to pursue enforcement actions against Spero. In addition, the FDA’s re‑filing of the NDA for the oral carbapenem tebipenem HBr triggers an expected $25 million milestone payment to Spero in Q1 2026, subject to acceptance of the filing. » More on de.investing.com
Spero Therapeutics beats Q2 expectations and stock rises
Spero Therapeutics reported Q2 2025 EPS of -$0.03 on revenue of $14.2 million, both well above expectations, and the stock rose double‑digit after the results. The company sharply reduced its net loss, extended its financing runway to 2028, and views Tebipenem HBr—after a successful Phase‑3 study—as on track for possible FDA approval in 2026. Challenges remain in the SPR720 program, and dependence on milestone payments continues to be a risk. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2015, SPERO THERAP.INC. DL-,001 has already paid €0.0534 in dividends. The last payout was in October 2015.
Financials
In the last quarter, SPERO THERAP.INC. DL-,001 had revenue of €0 and net profit of -€39.09M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | 0 | 100.00% |
| Net profit | -39.09M | 521.43% |
| EBITDA | -6.1M | 2.27% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €46.41M |
Number of shares | 58.26M |
52-week high/low | €2.81 - €0.79 |
| Dividends | No |
Beta | 1.56 |
P/E ratio | -1.78 |
PEG ratio | 0.00 |
P/B ratio | 65.16 |
P/S ratio | 1.28 |
Company profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Name | SPERO THERAP.INC. DL-,001 |
| CEO | Esther Rajavelu |
| Headquarters | Cambridge,
ma USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 11/02/2017 |
| Employees | 25 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SPRO |
Frankfurt | 2HA.F |
DĂĽsseldorf | 2HA.DU |
MĂĽnchen | 2HA.MU |